View in EDS

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.

Saved in:
Bibliographic Details
Title: Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
Authors: Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea., Gadgeel S; Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan., Gettinger SN; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Riely GJ; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Oxnard GR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Mekhail T; AdventHealth Cancer Institute, Orlando, Florida., Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Dowlati A; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio., Heist RS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wozniak AJ; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Singh J; Genentech, Inc., South San Francisco, California., Cha E; Genentech, Inc., South San Francisco, California., Spahn J; Genentech, Inc., South San Francisco, California., Ou SI; University of California Irvine School of Medicine, Orange, California.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2022 Jun 25; Vol. 3 (8), pp. 100367. Date of Electronic Publication: 2022 Jun 25 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35875467
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kim+DW%22">Kim DW</searchLink>; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Gadgeel+S%22">Gadgeel S</searchLink>; Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.<br /><searchLink fieldCode="AU" term="%22Gettinger+SN%22">Gettinger SN</searchLink>; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Riely+GJ%22">Riely GJ</searchLink>; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.<br /><searchLink fieldCode="AU" term="%22Oxnard+GR%22">Oxnard GR</searchLink>; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Mekhail+T%22">Mekhail T</searchLink>; AdventHealth Cancer Institute, Orlando, Florida.<br /><searchLink fieldCode="AU" term="%22Schmid+P%22">Schmid P</searchLink>; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Dowlati+A%22">Dowlati A</searchLink>; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio.<br /><searchLink fieldCode="AU" term="%22Heist+RS%22">Heist RS</searchLink>; Massachusetts General Hospital Cancer Center, Boston, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Wozniak+AJ%22">Wozniak AJ</searchLink>; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.<br /><searchLink fieldCode="AU" term="%22Singh+J%22">Singh J</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Cha+E%22">Cha E</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Spahn+J%22">Spahn J</searchLink>; Genentech, Inc., South San Francisco, California.<br /><searchLink fieldCode="AU" term="%22Ou+SI%22">Ou SI</searchLink>; University of California Irvine School of Medicine, Orange, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101769967%22">JTO clinical and research reports</searchLink> [JTO Clin Res Rep] 2022 Jun 25; Vol. 3 (8), pp. 100367. <i>Date of Electronic Publication: </i>2022 Jun 25 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Inc%22">Elsevier Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101769967 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-3643 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226663643%22">26663643 </searchLink><i>NLM ISO Abbreviation: </i>JTO Clin Res Rep <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35875467
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2022.100367
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 100367
    Titles:
      – TitleFull: Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kim DW
      – PersonEntity:
          Name:
            NameFull: Gadgeel S
      – PersonEntity:
          Name:
            NameFull: Gettinger SN
      – PersonEntity:
          Name:
            NameFull: Riely GJ
      – PersonEntity:
          Name:
            NameFull: Oxnard GR
      – PersonEntity:
          Name:
            NameFull: Mekhail T
      – PersonEntity:
          Name:
            NameFull: Schmid P
      – PersonEntity:
          Name:
            NameFull: Dowlati A
      – PersonEntity:
          Name:
            NameFull: Heist RS
      – PersonEntity:
          Name:
            NameFull: Wozniak AJ
      – PersonEntity:
          Name:
            NameFull: Singh J
      – PersonEntity:
          Name:
            NameFull: Cha E
      – PersonEntity:
          Name:
            NameFull: Spahn J
      – PersonEntity:
          Name:
            NameFull: Ou SI
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 06
              Text: 2022 Jun 25
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 2666-3643
          Numbering:
            – Type: volume
              Value: 3
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: JTO clinical and research reports
              Type: main
ResultId 1